the daunorubicin-poly-l-aspartic acid conjugate demonstrated antitumor activity comparable to that of doxorubicin in leukemia models , but superior to that of doxorubicin in a solid tumor model ( ms-2 sarcoma ) .
C0280100
solid tumor
C1261473
sarcoma